Current Research on GLP-1 Drugs and Muscle Mass A 2022 systematic review in Obesity Reviews found that GLP-1 medication-associated weight loss showed comparable or slightly better muscle preservation than diet-only approaches
Cell 185(14):2478-2494.e28 Zheng Z, Zong Y, Ma Y, Tian Y (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
In the coming years, patients and providers will have the options of newly launched biosimilars, novel GLP-1s, combination drugs, and approvals for allied indications
Ji C, Xue GF, Lijun C, Feng P, Li D, Li L, Li G, Hlscher C
This shift both reflects increasing consumer understanding of products that can support their health goals and growing opportunities for beverage manufacturers to develop solutions that support these consumer expectations related to weight management and metabolic wellness. Understanding the reasons As Americans awareness of GLP-1 agonists grows, the reasonings behind adoption comes from a wide range
